Related references
Note: Only part of the references are listed.Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study
Carlo Visco et al.
LEUKEMIA (2021)
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy
Rory McCulloch et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma
David A. Bond et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2020)
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
Peter Martin et al.
BLOOD (2019)
Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up
Simon Rule et al.
BLOOD (2019)
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death
Carlo Visco et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study
Sasanka M. Handunnetti et al.
BLOOD (2019)
Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis
Simon Rule et al.
HAEMATOLOGICA (2019)
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study
Matthew S. Davids et al.
LANCET HAEMATOLOGY (2019)
Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party
Stephen P. Robinson et al.
BONE MARROW TRANSPLANTATION (2018)
Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN)
Alexandra Smith et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Constantine S. Tam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
Mats Jerkeman et al.
LANCET HAEMATOLOGY (2018)
Incidence and survival trends in mantle cell lymphoma
Narendranath Epperla et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies
Simon Rule et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Dreyling et al.
ANNALS OF ONCOLOGY (2017)
Postibrutinib outcomes in patients with mantle cell lymphoma
Peter Martin et al.
BLOOD (2016)
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
HAEMATOLOGICA (2016)
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
HAEMATOLOGICA (2016)
Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study
Anna Abrahamsson et al.
BLOOD (2014)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)